This gives a rationale to evaluate EZH2 inhibition as a potential new therapy of T-cell lymphomas, as a single agent but also in combination with cytotoxic agents, which is currently discussed [13]. This evidence concerns the gene EZH2 and T-cell non-Hodgkin lymphoma.